Electroporation-mediated transcatheter arterial chemoembolization in the rabbit VX2 liver tumor model

Investigative Radiology

Volumn 47, Issue 2, 2012, Pages 116-120

  Guo, Yang ^a   Zhang, Yue ^a,b   Jin, Ning ^a,c,d   Klein, Rachel ^a   Nicolai, Jodi ^a   Lewandowski, Robert J ^a   Ryu, Robert K ^a   Omary, Reed A ^a,c   Larson, Andrew C ^a,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b University of Illinois at Chicago   (United States)

^c Northwestern University   (United States)

^d Siemens Healthcare   (United States)

Author keywords

electroporation; inductively coupled plasma mass spectroscopy (ICP MS); liver cancer; MRI; transcatheter arterial chemoembolization (TACE)

Indexed keywords

CISPLATIN; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMOEMBOLIZATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIGITAL SUBTRACTION ANGIOGRAPHY; DRUG BLOOD LEVEL; DRUG UPTAKE; ELECTRODE; ELECTROPORATION; EXPERIMENTAL RABBIT; LIVER TUMOR; MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TUMOR MODEL; TUMOR VOLUME;

EID: 84855827833     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e31822e57cc     Document Type: Article

References (22)

1. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology. 2010;52:762-773.
2. Lencioni R. Loco-regional treatment of hepatocellular carcinoma in the era of molecular targeted therapies. Oncology. 2010;78(suppl 1):107-112.
3. Wang B, Xu H, Gao ZQ, et al. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol. 2008;49:523-529.
4. Sergio A, Cristofori C, Cardin R, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol. 2008;103:914-921. (Pubitemid 351506379)
5. Li X, Feng GS, Zheng CS, et al. Influence of transarterial chemoembolization on angiogenesis and expression of vascular endothelial growth factor and basic fibroblast growth factor in rat with Walker-256 transplanted hepatoma: an experimental study. World J Gastroenterol. 2003;9:2445-2449. (Pubitemid 37461245)
6. Liapi E, Geschwind JF. Intra-arterial therapies for hepatocellular carcinoma: where do we stand? Ann Surg Oncol. 2010;17:1234-1246.
7. Rubinsky B. Irreversible electroporation in medicine. Technol Cancer Res Treat. 2007;6:255-260.
8. Testori A, Tosti G, Martinoli C, et al. Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach. Dermatol Ther. 2010;23:651-661.
9. Sersa G, Krzic M, Sentjurc M, et al. Reduced blood flow and oxygenation in SA-1 tumours after electrochemotherapy with cisplatin. Br J Cancer. 21 2002;87:1047-1054. (Pubitemid 35305660)
10. Larson AC, Wang D, Atassi B, et al. Transcatheter intraarterial perfusion: MR monitoring of chemoembolization for hepatocellular carcinoma-feasibility of initial clinical translation. Radiology. 2008;246:964-971.
11. Wang D, Bangash AK, Rhee TK, et al. Liver tumors: monitoring embolization in rabbits with VX2 tumors-transcatheter intraarterial first-pass perfusion MR imaging. Radiology. 2007;245:130-139. (Pubitemid 47417796)
12. Chandarana H, Block TK, Rosenkrantz AB, et al. Free-breathing radial 3D fat-suppressed T1-weighted gradient echo sequence: a viable alternative for contrast-enhanced liver imaging in patients unable to suspend respiration. Invest Radiol. 2011;46:648-653.
13. Guo Y, Zhang Y, Nijm GM, et al. Irreversible electroporation in the liver: contrast-enhanced inversion-recovery MR imaging approaches to differentiate reversibly electroporated penumbra from irreversibly electroporated ablation zones. Radiology. 2011;258:461-468.
14. Zhang Y, Guo Y, Ragin AB, et al. MR imaging to assess immediate response to irreversible electroporation for targeted ablation of liver tissues: preclinical feasibility studies in a rodent model. Radiology. 2010;256:424-432.
15. Rubinsky B, Onik G, Mikus P. Irreversible electroporation: a new ablation modality-clinical implications. Technol Cancer Res Treat. 2007;6:37-48. (Pubitemid 46389347)
16. Guo Y, Zhang Y, Klein R, et al. Irreversible electroporation therapy in the liver: longitudinal efficacy studies in a rat model of hepatocellular carcinoma. Cancer Res. 2010;70:1555-1563.
17. Haemmerich D, Staelin ST, Tsai JZ, et al. In vivo electrical conductivity of hepatic tumours. Physiol Meas. 2003;24:251-260. (Pubitemid 36648393)
18. Miklavcic D, Semrov D, Mekid H, et al. A validated model of in vivo electric field distribution in tissues for electrochemotherapy and for DNA electrotransfer for gene therapy. Biochim Biophys Acta. 2000;1523:73-83.
19. Cemazar M, Miklavcic D, Scancar J, et al. Increased platinum accumulation in SA-1 tumour cells after in vivo electrochemotherapy with cisplatin. Br J Cancer. 1999;79:1386-1391. (Pubitemid 29116794)
20. Ramirez LH, Orlowski S, An D, et al. Electrochemotherapy on liver tumours in rabbits. Br J Cancer. 1998;77:2104-2111. (Pubitemid 28263929)
21. Liapi E, Georgiades CC, Hong K, et al. Transcatheter arterial chemoembolization: current technique and future promise. Tech Vasc Interv Radiol. 2007;10:2-11. (Pubitemid 350008078)
22. Voth M, Rosenberg M, Breuer J. Safety of gadobutrol, a new generation of contrast agents: experience from clinical trials and postmarketing surveillance. Invest Radiol. 2011;46:663-671.